Nagi Bioscience: Nagi Bioscience obtains CHF 1.8 Million Seed funds

With its Organism-on-Chip technology, the Lausanne based Nagi Bioscience seeks aims to set a new standard for in Vitro testing safety and efficacy of drugs and chemicals. To achieve this mission, Nagi Bioscience has raised CHF 1.8 million in its seed round to complete the development of its first product and accelerate commercialisation.